The company’s shift to the U.S. market involves rapid scaling of logistics and distribution infrastructure. This transition coincides with a strengthened clinical profile, marked by new cost-effectiveness data from Italy and expanded hospital reimbursement pathways in Germany. As of June 30, 2026, the firm held 41.7 million euros in cash and equivalents, providing a runway for its commercial launch activities.

European operations continue to provide a stable foundation, with the network of Centers of Excellence growing to over 60 locations. Recent additions include the MD Anderson Madrid facility and new sites across Switzerland and the UK. Financially, the company managed to narrow its operating loss to 4.2 million euros for the quarter, down from 4.5 million euros in the same period last year, while maintaining a high adjusted gross margin of 94%.